Item 1(a). | Name of Issuer: |
Viridian Therapeutics, Inc. (the “Issuer”)
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
221 Crescent Street, Suite 401
Waltham, MA 02453
Item 2(a). | Names of Persons Filing: |
The names of the persons filing this report (collectively, the “Reporting Persons”) are:
Perceptive Advisors LLC (“Perceptive Advisors”)
Joseph Edelman (“Mr. Edelman”)
Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)
Item 2(b). | Address of Principal Business Office or, if None, Residence: |
The address of the principal business office of each of the Reporting Persons is:
51 Astor Place, 10th Floor
New York, NY 10003
Perceptive Advisors is a Delaware limited liability company
Mr. Edelman is a United States citizen
The Master Fund is a Cayman Islands corporation
Item 2(d). | Title of Class of Securities: |
Common stock, $0.01 par value per share (“Common Stock”)
92790C 104
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on an aggregate of 59,728,897 shares of Common Stock outstanding, which consists of (i) 52,586,039 shares of Common Stock outstanding as of November 7, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 13, 2023, and (ii) 7,142,858 shares of Common Stock sold by the Issuer in a registered public offering, as reported by the Issuer in the Issuer’s prospectus supplement filed with the SEC on January 19, 2024.